Enterohemorrhagic
Escherichia coli (EHEC) are a group of Gram Negative bacteria belonging to Enterobacteriaceae
family that are a significant cause of infantile diarrhea and hemolytic uremic syndrome in the developing and developed nations
[
1]. Infections are usually transmitted following ingestion of unhygienic packed
and processed food, milk and water resources. One typical EHEC,
Escherichia coli O157:H7, also known as verotoxigenic
Escherichia coli (E. coli) or shiga like toxin producing E coli, is the causative agent of hemorrhagic colitis
[
1]. These organisms have been characterized to produce virulence factors like
periplasmic catalases and shiga-like toxins which act by catalytically inactivating 60S ribosomal subunit of the eukaryotic protein
translation machinery [
1,
2].
The verotoxin it self is expressed by a prophage carried by the
E.coli strains. The periplasmic catalase is plasmid
mediated (pO157 plasmid) and provides oxidative protection during infection.
E coli O157:H7 fail to show pathogenicity
factors seen in other pathogenic
E coli and hence cannot be cultured on plates containing bile salts
[
2]. As a consequence, studies on these hemorrhagic pathogens have been limited
and effective means of preventing EHEC have not been elucidated.
E coli O157:H7 was first indicated in food borne illness in the USA in 1982
[
1]. In India, the emergence of infections with
E coli O157:H7
was first reported in 1999 by Pal and colleagues [
3]. A comprehensive review of
the molecular epidemiology of
E coli O157:H7 in India is reported by Wani and colleagues [
4].
The recent emergence of this infectious EHEC as a biofilm former has further marked it for increased multiple antibiotic resistances and
made it imperative that new strategies should be investigated to curb such infections
[
1]. One such strategy for novel drug design is targeting metabolic pathways
present exclusively in prokaryotes. Vitamin biosynthesis pathways in prokaryotes that are absent in vertebrates provide such an
opportune metabolism. The thiamine (Vitamin B1) biosynthesis pathway represents a pathway that has been outlined for
Escherichia coli
as represented in and derived from MetaCyc database
[
5]. Thiazole (5-methyl-4-(β-hydroxyethyl) thiazole phosphate) and
the pyrimidine (4-amino-5-hydroxymethylpyrimidine pyrophosphate) moieties are separately synthesized. The pyrimidine is derived from
5aminoimidazole ribotide. The thiazole is derived from tyrosine, cysteine, and 1-deoxy-D-xylulose-5-phosphate. These are coupled by the
enzyme thiamine pyrophosphorylase kinase (thi E, 2.5.1.3) to form thiamine mono phosphate. A final phosphorylation step results in the
formation of thiamine pyrophosphate (THI-PP) which forms the biological active molecule. THI-PP, the metabolically important form of
vitamin B
1 is a cofactor of α-keto acid dehydrogenase complexes, the glycine cleavage system and enzymes such as
transketolase and pyruvate decarboxylase, important in carbohydrate metabolism. Five tightly linked genes have found to be involved in
thiamine biosynthesis called as the thi CEFGH cluster [
6]. Thi E forms the
crucial end point enzyme in the thiamine biosynthesis from different precursors and can be used for as a target for designing drugs
against
E coli OH: 157 ().
In this report, the Thi E enzyme of the TBS pathway was studied in the Enterohemorrhagic Escherichia coli OH: 157
using in silico approaches. The structural studies on the Thi E have not yet been elucidated. Here, the tertiary
structure of the protein is predicted using three different protein structure prediction tools. The best predicted 3D model has been
analyzed with respect to its structural features and the putative docking sites of the Thi E enzymes are predicted.